The assessment framework most clinicians were trained on was not designed for the cardiometabolic disease burden of the 21st century. Here is precisely where it falls short — and what the evidence says about the consequences.
Metabolic dysfunction-associated steatotic liver disease — fatty liver — affects one in three adults globally. It is simultaneously one of the most prevalent, most reversible, and most consistently underdetected conditions in clinical medicine.
A 2025 nationwide Swedish cohort study of 13,099 patients found that MASLD is associated with 85% higher all-cause mortality compared to the general population. The primary drivers of excess mortality were not liver failure — they were cardiovascular disease and cancer. Fatty liver is a cardiometabolic systems condition that kills people through the systems it disrupts, not primarily through the organ it begins in.
A 2026 meta-analysis of 52 studies found approximately twofold higher cardiovascular event risk in MASLD patients across diverse populations and study designs. The same meta-analysis identified a pragmatic panel of biomarkers — FLI, FIB-4, TyG index, blood pressure — that consistently associate with cardiovascular outcomes and can be deployed in routine practice. These tools exist. Most clinicians were not trained to use them as a system.
The critical finding from both studies is that this risk is not fixed. Regression of fatty liver is associated with measurable reduction in cardiovascular risk. The disease is reversible. The clinical window is real. What has been missing is the framework to find it, characterize it, and track its resolution.
Two landmark studies published in 2025 and 2026 quantify the cardiometabolic burden of MASLD with a precision that makes the clinical imperative unavoidable.
These are not abstract limitations. Each gap has a direct clinical consequence — a patient whose risk is missed, whose intervention is delayed, or whose response to treatment goes unconfirmed because the assessment framework was not designed to find these things.
These enzymes were designed to detect hepatocellular injury — the release of intracellular enzymes into the bloodstream following cell damage. They are not fatty liver screening tools. Fat accumulation in liver cells precedes damage, sometimes by years. A normal ALT result tells you the liver cells are not currently leaking. It tells you nothing about their fat content. Research from the NASH Clinical Research Network confirms that 30–40% of biopsy-verified fatty liver cases present with entirely normal ALT and AST. The tool being used for the job was built for a different job.
Source: NASH Clinical Research Network; multiple publications on noninvasive NAFLD/MASLD screening limitations.
Insulin resistance is the primary metabolic driver of hepatic fat accumulation. It is detectable — through direct measurement of fasting insulin and calculated resistance indices — years before fasting glucose or HbA1c become abnormal. The window in which standard metabolic panels detect dysfunction is the window after the dysfunction has already been compounding for years. Most standard lab panels do not include fasting insulin. The result is a systematic delay in identifying the condition's most important upstream driver.
MASLD generates adverse biomarker shifts across at least six domains simultaneously: hepatic enzymes, triglycerides, insulin resistance, LDL cholesterol, HDL cholesterol, and inflammatory markers. Each shift is subclinical when evaluated individually against a reference range. Together they describe a body under significant and measurable systemic strain. A framework that evaluates each domain independently — as standard clinical workflows do — cannot see the convergence. It sees six borderline-normal values instead of one coherent risk pattern.
Source: Zhong J et al. Am J Prev Cardiol. 2026;26:101415. — Systematic characterization of multi-domain biomarker shifts in MASLD vs. non-steatotic comparators.
The research is clear that regression of fatty liver is associated with measurable reduction in cardiovascular risk — this is not a theoretical outcome, it is documented in the literature. But measuring reversal requires the same multi-domain framework that identified the risk in the first place. Without a structured retesting protocol against meaningful biomarker benchmarks, clinical management becomes impressionistic. The intervention may be working. Without the right monitoring architecture, you cannot confirm it with data.
CMiQCertified training gives you the assessment architecture, the interpretive framework, and the structured protocols to close each of these gaps in your practice. Enrollment is opening by metro area.